World Sleep Industry ENCYCLOPEDIA

Biosample Management

6.5.2

Definition, managed objects, and service boundaries

Biosample management is the lifecycle control of human blood, serum or plasma, saliva, urine, stool, hair, swabs, cells, tissues, and their simple derivatives according to a research purpose, ethics authorization, and quality requirements. It covers planning, collection handoff, coding, processing, aliquoting, preservation, retrieval, distribution, and final disposition. This entry sits in WSIC 6.5.2, “Participant and Sample Management.” The core deliverable is not putting tubes in a freezer. It is ensuring that each material’s identity, permitted use, preanalytical history, current location, and remaining status are traceable and correctly linked to the corresponding research data.

This entry is distinct from participant recruitment, outsourced sample testing and storage, management of a particular specimen type, analytical laboratory work, and clinical diagnosis. A manager may receive, process, inventory, and release material but cannot interpret a test result or expand research use merely by being the custodian. A testing laboratory does not gain unlimited retention, secondary-research, or commercialization rights simply because a sample arrived. Clinical residual material, samples newly collected for research, legacy collections, and material transferred from another institution have different authorization and evidence chains and do not become equivalent when assigned a new number.

The protocol, sample-management plan, and agreements should define material types, planned quantities, authorized users, processing windows, storage conditions, retention, permitted use, interinstitutional transfer, return of results, depletion rules, and end-of-project disposition. Investigator, sponsor, collection site, courier, central laboratory, biobank, and analytical team need a responsibility matrix. Outsourcing an activity does not transfer ultimate responsibility for informed consent, participant rights, fitness of the material for purpose, or reliability of study results.

Governance, consent, and use control

Before building a collection, the research question should be converted into a justified sample need: why the material is required, what and when to collect, how much per visit, whether repeated measures are necessary, which analyses require retained source material, and whether future uses are reasonably foreseeable. Volume and aliquot plans should balance scientific value, participant burden, analytical sensitivity, repeat testing, equipment capacity, and cost. Collection without boundaries “in case it is useful later” is not a sufficient purpose. When clinical and research draws occur together, extra volume, labels, and result pathways should not become confused.

Informed consent and the governing requirements determine what is permitted. Information may need to address the collection procedure and risks, retention period, sharing, institutions that may obtain access, cross-border movement, genetic or other highly sensitive analysis, future research, commercial development, recontact, withdrawal, destruction, and whether individual findings or incidental findings may be returned. Research consent, consent for clinical care, privacy authorization, and a material-transfer agreement perform different functions. A broad phrase such as “for research” may not support every secondary use, and de-identification does not automatically remove every ethical, group, or re-identification risk.

Each sample should remain bound to the current consent scope, protocol version, ethics approval, restrictions, and withdrawal status. Before secondary research, interinstitutional sharing, genomic analysis, method development, teaching, or a commercial collaboration begins, an authorized body should determine whether the activity is within the approved scope rather than leaving the decision to repository staff. After withdrawal, the system should distinguish unused, distributed, depleted, incorporated into non-retractable aggregate results, and legally required retained material according to what participants were told, documenting both actions that can be completed and material that cannot be recalled.

Collection design and sleep-phase metadata

Collection instructions should define the container, additive, preservative or stabilizer, volume, order, mixing, light protection, posture, fasting or meal conditions, exercise, oral hygiene, collection duration, and delivery window for the material and intended analysis. Actual collector, place, date, start and finish times, device or consumable lot, collection difficulty, contamination, hemolysis, insufficient quantity, leakage, and deviations should also be captured. Labels should be generated or confirmed at the collection point after identity verification rather than reconstructed from memory. A failed or missed collection must remain distinct from a negative analytical result.

Time in sleep research is more than a clock reading. Dates crossing midnight, time zone, daylight-saving status, sleep and wake times, sleep stage, elapsed time from awakening, shift work, travel, light exposure, posture, meals, caffeine, alcohol, smoking, exercise, acute illness, medication, and treatment may all change interpretability. Rhythmic measures such as melatonin and cortisol require alignment to the individual’s sleep phase and protocol conditions. A delayed waking saliva specimen, bright-light contamination during a dim-light series, or a missed interval in a timed urine collection cannot be hidden behind the scheduled time printed on a label.

Home collection requires validation of the full pathway, not merely shipment of a kit. Instructions should fit the target language, vision, cognition, and manual ability; containers and error-resistant steps should be clear; and the plan should address time recording, temperature, leaks, insufficient samples, inability to ship the same day, and support contacts. Electronic reminders, photographs, timestamps, or sensors can aid verification but do not prove correct execution. Monitoring intensity must also respect privacy and accessibility so that a lack of smartphone access or stable connectivity does not systematically exclude participants.

Receipt, processing, aliquoting, and storage

At receipt, staff should inspect seals, container integrity, labels against manifests, material type, quantity or volume, temperature records, collection and arrival times, and biosafety risk. Predefined criteria should lead to acceptance, quarantine, conditional acceptance, or rejection. Leakage, mislabeling, an exceeded time window, temperature excursion, missing consent status, or an identity conflict belongs in a deviation process and must not be backfilled as conforming to improve completion rates. The link between source identity and repository code should be maintained in a controlled system, and manual corrections should preserve the original value, reason, person, and time.

Processing should be controlled by a validated method or one shown suitable for purpose. Relevant steps include standing or clotting, centrifugation time, temperature, force, and brake, cell separation, stabilization, filtration, mixing, aliquoting, temporary holding, and transfer into long-term storage. The same nominal specimen type does not make processes interchangeable. Serum and different anticoagulated plasmas, spot and timed urine, whole stool and preservative-treated material, viable cells and extracted nucleic acids have different constraints. Changes in equipment, consumables, reagents, operator, or processing location require an assessment of comparability with existing material.

The aliquot plan should reduce repeated freeze-thaw exposure while assigning practical volumes for planned analysis, quality control, repeat work, and long-term retention. Every parent tube, child tube, pool, and derivative relationship should be traceable; specimens from different visits or with different prehandling histories must not be merged into one apparent batch. Storage temperature and container should be selected for the target analyte and available stability evidence rather than from a universal assumption that ultralow temperature is always sufficient. Actual position, movements, exposure, freeze-thaw count, remaining quantity, expiry, or reevaluation status should be recorded.

Inventory, chain of custody, transport, and distribution

The inventory system should assign a unique identifier to every container and maintain controlled relationships among participant, visit, material, aliquot, location, consent restriction, quality status, and request. Reconciliation should compare the database with physical location, label readability, empty containers, duplicate barcodes, quantity, and movement history. Access should follow least privilege, with dual checks for high-value or restricted material. Printed worklists, temporary labels, and offline records must be reconciled or destroyed rather than becoming a second truth outside the system.

Chain of custody extends from collection to final consumption or destruction. Each handoff should record sender and recipient, time, quantity, packaging, temperature condition, purpose, and exceptions. Opening a package, moving a rack, refreezing, subsampling, and returning material are part of that history. Before transport, material should be classified for hazard, temperature, and jurisdiction, then matched to qualified receptacles, absorbent and secondary leak protection, outer packaging, coolant, labeling, documentation, and trained carriers. Delay, loss, breakage, customs hold, and temperature excursion require predefined contacts and disposition decisions.

Distribution should pass scientific, ethics, and resource review that confirms the purpose, minimum quantity, method compatibility, data needs, outputs, and handling of residual material. Scarce material need not be allocated solely on a first-come basis; scientific value, feasibility, participant authorization, fairness, and prior commitments may all matter. Identity, quality, and restrictions should be rechecked before release, with receipt confirmed and unauthorized onward transfer prohibited. Whether returned residuals or derivatives can reenter inventory should be predefined with their new processing history; they cannot be assumed equivalent to their pre-release state.

Quality, safety, data, and privacy

The quality system should cover document control, staff competency, equipment qualification and maintenance, temperature mapping and calibration, reagents and consumables, environmental and biosafety controls, suppliers, deviations, nonconformities, corrective and preventive action, change, internal audit, and management review. Quality is not proven merely because a tube still exists; the question is whether the material remains fit for its intended use. Representative quality indicators, process controls, stability work, or sampled testing may monitor collection drift, but a single passing assay does not establish suitability of every aliquot, analyte, or future method.

Samples may contain infectious material, chemical preservatives, or cryogenic media and may reveal genetic, disease, medication, reproductive, behavioral, and family-relationship information. Risk assessment should cover staff exposure, sharps, aerosols, oxygen displacement by liquid nitrogen, cold burns, transport incidents, unauthorized access, and misuse. High-consequence material requires specialized facilities, training, and oversight, while ordinary human material does not become biologically harmless because it has been coded. Incident response should protect people, isolate material, preserve records, and provide required notifications.

Samples and data should use separated identifiers, with layered access, encryption, backup, logging, and periodic review for the linkage key, clinical information, temporal phenotype, and analytical results. Genomic and multi-omic information may reconnect an individual or relatives through combined data, so removal of a direct name is not synonymous with anonymity. Before sharing, the repository should review consent, data-use restrictions, recipients, onward sharing, result return, and destruction evidence. Algorithm training, commercial profiling, law-enforcement, or insurance use must not be treated as implicitly permitted by a general research authorization.

Procurement acceptance, continuity, and final disposition

Before procuring or outsourcing biosample management, the organization should examine applicable qualifications and accreditation scope, experience with comparable material, information systems, capacity, staffing, supply chain, temperature monitoring, backup power and equipment, disaster recovery, and exit capability. Acceptance testing should use realistic controlled scenarios: identity conflict, low volume or wrong container, collection across midnight, delayed home return, temperature drift, duplicate barcode, consent withdrawal, urgent retrieval, power failure, system outage, and carrier loss of contact. Pricing should separate kit, processing, aliquoting, space, retrieval, shipping, data, long-term maintenance, and destruction so that a low intake fee does not become vendor lock-in through retrieval charges.

Operating measures may include planned versus actual collections, receipt acceptance, processing timeliness, temperature excursions, freeze-thaw exposure, inventory accuracy, request turnaround, depletion, identity or consent conflicts, complaints, and incident closure, always with an explicit denominator and purpose. A “zero deviation” target must not reward concealment, and a temperature trace alone cannot establish molecular integrity. Trends should be stratified by site, material, equipment, shipment, and time; a systematic difference should trigger evaluation of legacy material, ongoing studies, and any published result that might be affected.

At project end, repository closure, or vendor change, consent, agreement, law, and the scientific plan should govern transfer, return, continued retention, de-identification, or destruction. Migration requires a tube-level manifest, receipt confirmation, temperature and custody history, database and audit trail, consent restrictions, open deviations, and access roles. Destruction should be irreversible and documented and should cover backup labels and residual material. Trustworthy biosample management ultimately demonstrates that participant authorization continued to govern the material, sample history was not forgotten, and researchers received material fit for the claimed purpose rather than only a barcode and a temperature reading.